UK biotech company Myricx Bio has taken space at Kadans Science Partner’s London Innovation Centre at 20 Water Street, Canary Wharf, for its new HQ.
The company, which is focused on the discovery and development of a completely novel class of payloads for antibody-drug conjugates for the treatment of cancer, is taking a mix of laboratory and office space at the 40,000 sq ft innovation centre. Kadans would not disclose the square footage Myricx has taken.
Julie Mead, COO of Myricx Bio, said: “We are excited to take this next step and join Kadans’ London Innovation Centre as we grow our in-house R&D capabilities and management team, following the recent close of our £90m Series A financing. When looking to expand our footprint, it was important to us that we located a supportive, well-connected and dynamic environment in London, where we were founded, especially as we prepare to become a clinical stage company.
“We have found that environment in the Canary Wharf ecosystem, where the London Innovation Centre offers us excellent lab and office facilities, as well as a wider biotech network, which together will support our next phase of growth.”
Katie Nelson, head of leasing UK and Ireland at Kadans Science Partner, added: “We are really pleased that Myricx has chosen the London Innovation Centre to establish its headquarters, joining the growing community of life sciences companies at the facility and across the Canary Wharf estate. Kadans Science Partner’s ethos is to support our tenants with the full life cycle of their journey through its connected ecosystem which we can do across our London, UK and European Portfolio.
“It is encouraging to further expand our community at the London Innovation Centre, where we are seeing continued demand for flexible, high quality, affordable lab facilities in London. Myricx is an example of an innovative, growing business recognising the benefits of being situated in Canary Wharf’s growing science, health and technology district, with a community committed to collaboration and innovation.”
